Search
ROG.VX: Roche files single arm BIRCH in a forest of overall survival
Too little too late
Roche today announced that the FDA accepted its filing for atezolizumab in 2nd line PD‑L1 +ve Non-Small cell lung cancer with a PDUFA data of 19th October. However this filing appears to be based on the 530 patients from the single arm BIRCH study which did not compare to standard chemotherapy...
